The Clinical Summary of 312 Cases of Differentiated Thyroid Cancer Metastases with 131I Treatment

朱瑞森,余永利,陆汉魁,罗全勇,陈立波,朱继芳,袁志斌,朱珺,马寄晓
DOI: https://doi.org/10.3760/cma.j.issn.2095-2848.2002.06.001
2002-01-01
Abstract:ObjectiveThree hundred and twelve thyroid carcinoma patients with metastasis treated by the multiple 'high dose' program were followed up for 10 years. The results of 131I adverse effects were assessed. Methods1.Treatment protocol: In case of lung and bone metastasis, 7.4 GBq 131I was administered each time. For patients with lymphotic metastasis, 5.55 GBq 131I was given each time. The interval between 2 doses was 4 months. 2. Assessment of therapeutic results: negative 131I scanning was marked as cured, lesion size decrease, reduction of the number of foci or reduction of iodine uptake by the lesion, normal blood thyroglobulin (Tg) indicated effective treatment; higher blood Tg, appearance of new lesions with ensuing death were considered as treatment failure. 3. Adverse events: ①bone marrow inhibition; ② pulmonary function affected; ③parathyroid function affected; ④salivary glands affected; ⑤chromosome aberration. Results of the 312 patients: 112 (35.9%) were cured, effective treatment was shown in 118 patients (60.2%) and treatment failure in 12 cases (3.8%). ResultsTwo adverse events: ①Bone marrow inhibition. Cumulation of 131I could produce temporary reversible inhibition of bone marrow, no aplastic anemia was evident. ②Reversible changes were seen upon salivary glands. Submaxilla glandular function was slightly affected.③Effect on parathyroid function: PTH showed temporary change, without a single case of hypoparathyroidism. ④Effect on pulmonary function: no pulmonary function change or a single case of pulmonary fibrosis was seen. ⑤ Effect on the chromosome: After treatment, lymphocytes in peripheral blood showed aberration, in part of the patients, radioaction tolerability increased. Conclusions TBMultiple high dose therapy in treatment of metastatic thyroid carcinoma is an effective method. Indication can be extended to patients showing lymphatic metastases on operation. Adverse events seen in the study were almost neglegible. Good results were obtained and no aplastic anemia, hypoparathyroidism, decrease of pulmonary function, Sjgren's syndrome were seen.
What problem does this paper attempt to address?